Brain Natriuretic Peptide (BNP) Correlates Echo Finding of Hemodynamic Patent Ductus Arteriosus
Hamed, A., Elsayed, L., Aboushokka, R., Abdallah, H., Salama, R., El Gebaly, S. (2022). Brain Natriuretic Peptide (BNP) Correlates Echo Finding of Hemodynamic Patent Ductus Arteriosus. EKB Journal Management System, 89(1), 5784-5788. doi: 10.21608/ejhm.2022.266049
Ahmed Alaa Hamed; Lotfy Mohammed Elsayed; Rania Diaa Eldin Aboushokka; Hesham Mohamed Abdallah; Raafat Hassan Salama; Sherief m. El Gebaly. "Brain Natriuretic Peptide (BNP) Correlates Echo Finding of Hemodynamic Patent Ductus Arteriosus". EKB Journal Management System, 89, 1, 2022, 5784-5788. doi: 10.21608/ejhm.2022.266049
Hamed, A., Elsayed, L., Aboushokka, R., Abdallah, H., Salama, R., El Gebaly, S. (2022). 'Brain Natriuretic Peptide (BNP) Correlates Echo Finding of Hemodynamic Patent Ductus Arteriosus', EKB Journal Management System, 89(1), pp. 5784-5788. doi: 10.21608/ejhm.2022.266049
Hamed, A., Elsayed, L., Aboushokka, R., Abdallah, H., Salama, R., El Gebaly, S. Brain Natriuretic Peptide (BNP) Correlates Echo Finding of Hemodynamic Patent Ductus Arteriosus. EKB Journal Management System, 2022; 89(1): 5784-5788. doi: 10.21608/ejhm.2022.266049

Brain Natriuretic Peptide (BNP) Correlates Echo Finding of Hemodynamic Patent Ductus Arteriosus

The Egyptian Journal of Hospital Medicine
Article 260, Volume 89, Issue 1, October 2022, Page 5784-5788  XML PDF (723.13 K)
Document Type: Original Article
DOI: 10.21608/ejhm.2022.266049
View on SCiNiTO View on SCiNiTO
Authors
Ahmed Alaa Hamed email ; Lotfy Mohammed Elsayed; Rania Diaa Eldin Aboushokka; Hesham Mohamed Abdallah; Raafat Hassan Salama; Sherief m. El Gebaly
Abstract
Background: When Doppler echocardiography is not readily available, a biomarker like NT-pro-Brain Natriuretic Peptide (BNP) can be used to diagnose patent ductus arteriosus (PDA) in premature infants.
Objective: To evaluate the diagnostic accuracy of the cardiac biomarkers BNP for detection of hemodynamically significant patent ductus arteriosus (hsPDA) in preterm newborns and their correlation to echocardiography results.
Patients and Methods: At tertiary care hospital at National Heart Institute, a total of 46 premature neonates (< 34 weeks gestation) or those whose birth weight was less than 1200 g who were admitted to Neonatal Intensive Care Units (NICUs) were included in this cross-sectional study. Patients with PDA were classified as having either hsPDA or non-hsPDA based on a large ductal flow with left to right shunt on colour Doppler echocardiography, and all participating neonates underwent this evaluation between 48- and 72-hours following birth.
Results: Serum brain-type natriuretic peptide was statistically significantly higher in cases with hsPDA. Serum brain-type natriuretic peptide statistically had significant high diagnostic performance in predicting hemodynamically significant patent ductus arteriosus. Serum brain-type natriuretic peptide at cut-off value of ≥108.0 pg/mL, had moderate sensitivity, but high other characteristics in diagnosing hsPDA.
Conclusion: Preterm newborns at risk for poor outcome due to PDA may be identified by serum brain-type natriuretic peptide in combination with echocardiography.
 
Keywords
Brain Natriuretic Peptide; Patent Ductus Arteriosus
Statistics
Article View: 108
PDF Download: 225